EUVIMEDEUVIMED entdecken
Open Access

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine

Leah J McGrath, Deepa Malhotra, Amanda C Miles, Verna L Welch, Manuela Di Fusco, Andy Surinach, Andrea Barthel, Tamuno Alfred, Luis Jodar, John M McLaughlin

JAMA Network Open · 2023

DOI: 10.1001/jamanetworkopen.2023.42151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Network Open, 2023. Verfasst von Leah J McGrath und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, New York, New York. Hauptthemen laut MEDLINE: Influenza Vaccines, Influenza, Human, COVID-19. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance No data comparing the estimated effectiveness of coadministering COVID-19 vaccines with seasonal influenza vaccine (SIV) in the community setting exist.

Objective

To examine the comparative effectiveness associated with coadministering the BNT162b2 BA.4/5 bivalent mRNA COVID-19 vaccine (BNT162b2-biv [Pfizer BioNTech]) and SIV vs giving each vaccine alone. Design, Setting, and Participants A retrospective comparative effectiveness study evaluated US adults aged 18 years or older enrolled in commercial health insurance or Medicare Advantage plans and vaccinated with BNT162b2-biv only, SIV only, or both on the same day between August 31, 2022, and January 30, 2023. Individuals with monovalent or another brand of mRNA bivalent COVID-19 vaccine were excluded. Exposure Same-day coadministration of BNT162b2-biv and SIV; receipt of BNT162b2-biv only (for COVID-19–related outcomes) or SIV only (for influenza-related outcomes) were the comparator groups. For adults aged 65 years or older, only enhanced SIVs were included. Main Outcomes and Measures COVID-19–related and influenza-related hospitalization, emergency department (ED) or urgent care (UC) encounters, and outpatient visits.

Results

Overall, 3 442 996 individuals (57.0% female; mean [SD] age, 65 [16.7] years) were included. A total of 627 735 individuals had BNT162b2-biv and SIV vaccine coadministered, 369 423 had BNT162b2-biv alone, and 2 445 838 had SIV alone. Among those aged 65 years or older (n = 2 210 493; mean [SD] age, 75 [6.7] years; 57.9% female), the coadministration group had a similar incidence of COVID-19–related hospitalization (adjusted hazard ratio [AHR], 1.04; 95% CI, 0.87-1.24) and slightly higher incidence of emergency department or urgent care encounters (AHR, 1.12; 95% CI, 1.02-1.23) and outpatient visits (AHR, 1.06; 95% CI, 1.01-1.11) compared with the BNT162b2-biv–only group. Among individuals aged 18 to 64 years (n = 1 232 503; mean [SD] age, 47 [13.1] years; 55.4% female), the incidence of COVID-19–related outcomes was slightly higher among those who received both vaccines vs BNT162b2-biv alone (AHR point estimate range, 1.14-1.57); however, fewer events overall in this age group resulted in wider CIs. Overall, compared with those who received SIV alone, the coadministration group had a slightly lower incidence of most influenza-related end points (AHR point estimates 0.83-0.93 for those aged ≥65 years vs 0.76-1.08 for those aged 18-64 years). Negative control outcomes suggested residual bias and calibration of COVID-19–related and influenza-related outcomes with negative controls moved all estimates closer to the null, with most CIs crossing 1.00. Conclusions and Relevance In this study, coadministration of BNT162b2-biv and SIV was associated with generally similar effectiveness in the community setting against COVID-19–related and SIV-related outcomes compared with giving each vaccine alone and may help improve uptake of both vaccines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesInfluenza, HumanCOVID-19United StatesAdultAgedFemaleHumansMiddle AgedMaleBNT162 VaccineCOVID-19 VaccinesRetrospective StudiesMedicareRNA, Messenger

Substanzen

Influenza VaccinesBNT162 VaccineCOVID-19 VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Pfizer Inc, New York, New York.
  • Genesis Research Inc, Hoboken, New Jersey.

Zitieren

APA

McGrath, L. J., Malhotra, D., Miles, A. C., Welch, V. L., Di Fusco, M., Surinach, A., Barthel, A., Alfred, T., Jodar, L., & McLaughlin, J. M. (2023). Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.42151

Vancouver

McGrath LJ, Malhotra D, Miles AC, Welch VL, Di Fusco M, Surinach A, et al. Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.42151

BibTeX
@article{McGrath2023,
  author = {McGrath, Leah J and Malhotra, Deepa and Miles, Amanda C and Welch, Verna L and Di Fusco, Manuela and Surinach, Andy and Barthel, Andrea and Alfred, Tamuno and Jodar, Luis and McLaughlin, John M},
  title = {Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine},
  journal = {JAMA Network Open},
  year = {2023},
  doi = {10.1001/jamanetworkopen.2023.42151}
}
Kostenlos starten →